These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 3545965)
41. Controlled therapeutic trial to determine the optimum dose of antacids in duodenal ulcer. Kumar N; Vij JC; Karol A; Anand BS Gut; 1984 Nov; 25(11):1199-202. PubMed ID: 6389273 [TBL] [Abstract][Full Text] [Related]
42. Dose response inhibition in man of meal-stimulated gastric acid secretion by 15(R)-15-methyl prostaglandin E2, given orally. Robert A; Kane G; Reele SB Gut; 1981 Sep; 22(9):728-31. PubMed ID: 7297921 [TBL] [Abstract][Full Text] [Related]
43. The treatment of duodenal and gastric ulcer with ranitidine--a controlled, multicentre clinical trial. Gibinski K; Nowak A; Gabryelewicz A; Szalaj W; Hasik J; Klincewicz H; Pokora J; Radwan P; Kosecki P; Pachlewski J Dtsch Z Verdau Stoffwechselkr; 1982; 42(2-3):64-9. PubMed ID: 6286274 [TBL] [Abstract][Full Text] [Related]
44. Comparison of enprostil and cimetidine in active duodenal ulcer disease. Summary of pooled European studies. Winters L Am J Med; 1986 Aug; 81(2A):69-74. PubMed ID: 3092659 [TBL] [Abstract][Full Text] [Related]
45. [Evaluation of the efficacy and tolerance of enprostil, synthetic analog of prostaglandin E2, in a clinical study in double-blind vs. placebo]. Dal Monte PR; D'Imperio N; Sarti F; Cattoni M Clin Ter; 1988 Jun; 125(5):337-43. PubMed ID: 2974371 [No Abstract] [Full Text] [Related]
46. Famotidine versus cimetidine in the treatment of acute duodenal ulcer. Double-blind, randomized clinical trial comparing nocturnal administration of 40 mg famotidine to 800 mg cimetidine. Hartmann H; Fölsch UR Digestion; 1988; 39(3):156-61. PubMed ID: 3061859 [TBL] [Abstract][Full Text] [Related]
47. Antisecretory and serum gastrin lowering effect of enprostil in patients with duodenal ulcer disease. Mahachai V; Walker K; Sevelius H; Thomson AB Gastroenterology; 1985 Sep; 89(3):555-61. PubMed ID: 3926591 [TBL] [Abstract][Full Text] [Related]
48. Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. Reynolds JC; Schoen RE; Maislin G; Zangari GG Am J Gastroenterol; 1994 Apr; 89(4):571-80. PubMed ID: 8147361 [TBL] [Abstract][Full Text] [Related]
49. A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. Gitlin N; McCullough AJ; Smith JL; Mantell G; Berman R Gastroenterology; 1987 Jan; 92(1):48-53. PubMed ID: 2877912 [TBL] [Abstract][Full Text] [Related]
50. Accurate prediction of duodenal-ulcer healing rate by discriminant analysis. Lam SK; Koo J Gastroenterology; 1983 Aug; 85(2):403-12. PubMed ID: 6345257 [TBL] [Abstract][Full Text] [Related]
51. Pirenzepine and cimetidine for duodenal ulcers. A comparative randomised double-blind controlled study. Simjee AE; Bhoola RL; Spitaels JM; Manion GL S Afr Med J; 1988 Nov; 74(9):446-7. PubMed ID: 3055362 [TBL] [Abstract][Full Text] [Related]
52. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. Breiter JR; Riff D; Humphries TJ Am J Gastroenterol; 2000 Apr; 95(4):936-42. PubMed ID: 10763941 [TBL] [Abstract][Full Text] [Related]
53. Relationship between Sakita endoscopic stage and duration of treatment for duodenal ulcer healing. Mosci AS; Maletta CA; Castro FJ; Coelho LG; Vieira WL; Ribeiro TC; Castro LP Braz J Med Biol Res; 1989; 22(10):1219-23. PubMed ID: 2700432 [TBL] [Abstract][Full Text] [Related]
54. [Misoprostol and cimetidine in the treatment of active duodenal ulcer. Multicenter, double-blind, clinico-endoscopic study. The Argentine experience]. Baccaro JC; González del Solar C; Laudanno O; Mauro E; Mazure PA; Pardo R; Pulpeiro A; Rubio H; Tomatis H Acta Gastroenterol Latinoam; 1987; 17(3):235-40. PubMed ID: 3145665 [TBL] [Abstract][Full Text] [Related]
55. Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Martin DF; Hollanders D; May SJ; Ravenscroft MM; Tweedle DE; Miller JP Lancet; 1981 Jan; 1(8210):7-10. PubMed ID: 6109102 [TBL] [Abstract][Full Text] [Related]
56. 15(R)15 methyl prostaglandin E2 (Arbacet) has no effect on human gastric cell labeling index. Fich A; Arber N; Zajicek G; Rachmilewitz D Isr J Med Sci; 1988 Aug; 24(8):420-2. PubMed ID: 3045051 [No Abstract] [Full Text] [Related]